drugset / Trial / NCT04804553
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.
Timeline
- Start
- 2022-03-17
- Primary completion
- 2028-03-21
- Completion
- 2028-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | — | Oral |